tradingkey.logo

Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program

ReutersJan 11, 2026 8:01 PM

- Regenxbio Inc RGNX.O:

  • REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM

  • REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS

  • REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026

  • REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026

  • REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI